Updated Drug Labeling for Patient Safety Act

[AI summary unavailable — showing source text] [Congressional Bills 118th Congress] [From the U.S. Government Publishing Office] [S. 2886 Introduced in Senate (IS)] <DOC> 118th CONGRESS 1st Session S. 2886 To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES September 21, 2023 Mr. Van Hollen (for himself, Mr. Brown, Mr. Blumenthal, and Mr. Coons) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To permit manufacturers of generic drugs to provide additional warnings with respect to such drugs in the same manner that the Food and Drug Administration allows brand names to do so. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Updated Drug Labeling for Patient Safety Act''. SEC. 2. WARNING LABELING WITH RESPECT TO GENERIC D…